Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience
Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience
复制标题
DOI：
10.1007/s12282-015-0612-0
复制
发表时间：
2016-07-01
期刊：
影响因子：
4
通讯作者：
Yamashita, Hiroko
中科院分区：
文献类型：
--
作者：
Ishida, Naoko;Araki, Kazuhiro;Yamashita, Hiroko
FULVESTANT 500毫克目前被批准用于治疗激素受体阳性转移性乳腺癌的绝经后女性，此前的内分泌治疗失败。2012年1月至2014年6月期间，117名绝经后转移性乳腺癌患者在之前的内分泌治疗后病情恶化，接受了FUVESTANT 500 mg的治疗。对99例复发乳腺癌患者和18例IV期乳腺癌患者的临床反应、进展时间(TTP)和不良反应进行了研究。在服用福维斯特之前，患者接受过两次内分泌治疗的中位数和两次化疗的中位数。部分缓解10例，长期稳定39例，稳定18例，进展50例，客观有效率为8.5%，临床受益率为41.9%。中位TTP为6.1个月。单因素分析显示，无肝转移、既往少量化疗、一线内分泌治疗持续时间较长与TTP呈正相关。在多变量分析中，观察到TTP与一线内分泌治疗持续时间显著相关。在一名肺栓塞患者和一名精神症状患者中观察到了严重的不良事件。Fulvestrant 500 mg是一种有效且耐受性良好的治疗方法，用于治疗绝经后转移性乳腺癌，这些女性患者在之前的内分泌治疗后病情恶化。对内分泌治疗产生获得性抵抗的患者，无论以前接受过多少次内分泌治疗，都可能是福维司琼治疗的好对象。
Fulvestrant 500 mg is currently approved for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer after failure of prior endocrine therapies.A total of 117 postmenopausal women with metastatic breast cancer, who experienced progression after previous endocrine therapies, were treated with fulvestrant 500 mg between January 2012 and June 2014. Clinical response, time to progression (TTP) and adverse events were investigated.Ninety-nine patients had recurrent breast cancer and 18 patients had stage IV disease. Patients had received a median of two endocrine therapies and a median of two chemotherapies, prior to fulvestrant. There were 10 patients with partial response, 39 patients with long stable disease, 18 patients with stable disease, and 50 patients with progressive disease, so that the objective response rate was 8.5 %, with a clinical benefit rate of 41.9 %. The median TTP was 6.1 months. The absence of liver metastases, a small number of previous chemotherapies, and the longer duration of first-line endocrine therapy were positively correlated with TTP in univariate analysis. In multivariate analysis, a significant association was observed between TTP and duration of first-line endocrine therapy. Serious adverse events were observed in one patient with pulmonary embolism and in one patient with psychiatric symptoms.Fulvestrant 500 mg is an effective and well-tolerated treatment for postmenopausal women with metastatic breast cancer that had progressed after prior endocrine therapies. Patients with acquired resistance to endocrine therapies might be good candidates for fulvestrant therapy regardless of the number of prior endocrine treatments.